September 14, 2023 – We are thrilled to announce a groundbreaking collaboration between MORSE Consulting and Medlior Health Outcomes Research, two leaders in the Canadian pharmaceutical market access landscape. This partnership aims to blend MORSE Consulting’s unparalleled expertise in payer and HTA strategies with Medlior’s cutting-edge real-world evidence solutions, offering our clients an unmatched array of services to navigate the complex world of pharmaceutical market access.
MORSE Consulting is a leader in Canadian market access strategy, known for its bespoke solutions and client-centric approach. With a team of professionals boasting extensive experience in payers, HTA, pCPA negotiations, and market access strategy consulting, MORSE Consulting provides unparalleled insights that set it apart from any other consultancy in Canada. Our advice is grounded in authentic and credible communication, and our comprehensive range of services, including pCPA assessment & negotiation simulation and HTA strategic advice, ensures that our clients are well-prepared for every stage of their market access journey.
Medlior is a leading independent Canadian research organization specializing in real-world evidence, health technology submissions, and evidence synthesis. Their team’s RWE expertise spans from managing ethics approval and engaging in research agreements with data custodians, to conducting complex data linkages and analyses. With a focus on client-centric project management and delivery, Medlior offers a wide range of HTA and Evidence Synthesis services, including systematic literature reviews, economic evaluations, and medical writing, tailored to meet their clients’ needs in Canada and globally.
Our first collaborative service, the Advanced Innovative Agreements/Real World Evidence (RWE) Workshop, empowers pharmaceutical companies to shape successful market access strategies. This workshop addresses the unique challenges posed by innovative therapies like cell and gene therapies, drugs for rare diseases, and precision oncology. By leveraging MORSE Consulting’s expertise in reimbursement strategy and Medlior’s expertise in real-world evidence, we offer a comprehensive and customized approach to meet the specific needs of your product. This workshop is an invaluable resource for pharmaceutical companies at any stage of drug development.
This service is just the beginning. We are actively exploring other avenues to expand our collaboration, aiming to provide even more value to our clients. If you want to learn more about how this collaborative venture can benefit your organization, please contact MORSE Consulting’s Director, Innovative Access Solutions, Sang Mi Lee (sangmi@morseconsulting.ca) or info@medlior.com for further information.
